Using atorvastatin to reduce lung inflammation after tuberculosis treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety and efficacy of atorvastatin, a cholesterol-lowering medication, in reducing persistent lung inflammation in adults who have completed treatment for tuberculosis (TB). The study is a double-blind, randomized, placebo-controlled trial that aims to determine if atorvastatin can enhance recovery by targeting inflammation and potential residual infection. Participants include both HIV-infected and uninfected adults who have shown a clinical response to TB treatment. The effectiveness will be measured using advanced imaging techniques like PET/CT to assess lung inflammation.

Why it matters

Who can join: the full rules

Inclusion Criteria

1. Has completed the written informed consent process prior to undergoing any pre-screening or screening evaluations and willing to undergo HIV testing
2. Age 18 to 65 years with body weight from 50 kg to 90 kg
3. Clinical response to TB treatment and sputum culture negative at week 16
4. Completed a 24-week course of standard TB treatment (4RHZE/2RH)
5. Defined as "cured" by the TB Control Program of South Africa

   Laboratory parameters within 30 days before enrolment:
6. For HIV-infected participants: receiving antiretroviral therapy for at least 12 weeks and suppressed HIV viral load within 30 days prior to enrolment
7. For HIV-infected participants: CD4 counts above 350 cells/µL within 30 days prior to enrolment
8. AST and ALT \<3x upper limit of normal (ULN)
9. Creatinine \<2x ULN
10. Hemoglobin \>7.0 g/dL
11. Platelet count \>50 x109 cells/L
12. Creatinine kinase \<2x ULN
13. Able and willing to return to follow-up
14. Willing to have samples, including DNA, stored
15. Willing to consistently practice a highly reliable method of pregnancy prevention

Exclusion criteria

1. Acute illness
2. Fever (temperature \>38.0 degrees centigrade)
3. Participant receiving any type of lipid lowering agent at the time of screening, within three months prior to screening or likely to require any lipid lowering agent in the near future.
4. Known allergy or contraindications to the investigational drug or any other statins
5. Evidence of drug-resistant TB
6. Extrapulmonary TB, including pleural TB and/or large pleural effusion
7. Pregnant or desiring/trying to become pregnant in the next 6 months
8. Unable to take oral medications
9. Diabetes as defined by point of care HbA1c≥6.5, random glucose≥200mg/dL (or 11.1mmol/L), fasting plasma glucose≥126mg/dL (or 7.0mmol/L), or the presence of any anti-diabetic agent (including traditional medicines) as a concomitant medicine
10. Disease complications or concomitant illnesses that may compromise safety or interpretation of trial endpoints, such as known diagnosis of chronic inflammatory condition (e.g. sarcoidosis, rheumatoid arthritis, connective tissue disorder)
11. Use of immunosuppressive medications, such as TNF-alpha inhibitors or systemic or inhaled corticosteroids, within the past 2 weeks
12. Use of any investigational drug in the previous 3 months
13. Alcohol and substance abuse which might interfere with medication adherence during the trial
14. Any person for whom the physician feels this study is not appropriate

Where it's running

• General Medicine & Global Health, Cape Heart Institute, Faculty of Health Sciences, University of Cape Town
  Observatory, Wc, South Africa Recruiting

Study contacts

• Principal investigator: Friedrich Thienemann, MD — University of Cape Town
• Study coordinator: Friedrich Thienemann, MD
• Email: friedrich.thienemann@uct.ac.za
• Phone: +27 21 406 6358

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• FAP PET/CT in adults with pulmonary TB

  This early-phase study tests whether a FAP PET/CT scan can map lung fibrosis in adults with pulmonary TB before starting treatment and after cure.

  Recruiting Early Phase 1 University of Pennsylvania · Philadelphia, Pennsylvania · NCT07830771

• Sorfequiline-based regimens for adults with newly diagnosed drug-sensitive pulmonary TB

  This study tests two sorfequiline-containing regimens, each with pretomanid and linezolid, to see if they are safe and effective in adults with newly diagnosed drug-sensitive pulmonary TB.

  Recruiting at 6 sites Phase 2 Global Alliance for TB Drug Development · Wentworth, Durban and 11 other locations · NCT07672405

• Digital health tool to help more people start TB preventive therapy

  A digital health approach is being tested to see if it helps household and close contacts of people with drug-sensitive pulmonary TB start TB preventive therapy better.

  Recruiting at 8 sites Arba Minch University · Arba Minch, South Ethiopia and 13 other locations · NCT07313995

• Ear acupuncture to reduce nausea and vomiting from tuberculosis medicines

  This trial will test whether press-needle ear acupuncture can reduce nausea and vomiting in people taking medicines for pulmonary tuberculosis.

  Recruiting Universitas Indonesia · Jakarta, Jakarta Timur · NCT07271225

• 18F-FAPI-74 PET imaging for lung fibrosis in tuberculosis

  This project tries to see if 18F-FAPI-74 PET scans can detect lung fibrosis in adults with active or recently treated tuberculosis.

  Recruiting Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio · NCT07077213

• Blood TB DNA test to track treatment progress

  This project will test whether levels of TB-derived cell-free DNA in the blood can track treatment response in adults newly diagnosed with tuberculosis.

  Recruiting University of Oxford · Tak · NCT06845618

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.